Advent in exclusive negotiations on Zentiva

17 April 2018 - Deborah Wilkes

Private-equity firm Advent International has entered into exclusive negotiations to acquire Sanofi's European generics business Zentiva.

Sanofi said the proposed deal would see Advent pay EUR1.92 billion (USD2.38 billion) for Zentiva. The French pharmaceutical company said Advent's offer was "firm, binding and fully financed".

The transaction is expected to close by the end of 2018.

Read all about the strategies of important OTC players, including Sanofi, in the OTC Company Strategies 2018 Report published by the OTCToolbox website in March 2018.
– 270 pages
– Executive Summary of key global OTC/consumer healthcare trends
– 18 OTC/consumer healthcare Company Strategy Profiles
Click here to purchase and download.
Annual Subscription holders can download the report for free by logging into the website.

Click tags below for more information on topics:

Sanofi Consumer Healthcare

Back to Industry News

Share this page: